Table of contents
February 2002 Vol 1 No 2
In this issue
p91 | doi:10.1038/nrn730
Editorial: New money for old rope?
p93 | doi:10.1038/nrd731
Research Highlights
Chemical genetics: Exploring chemical space
p95 | doi:10.1038/723
Immunomodulators: Antivirals pay the Toll
p96 | doi:10.1038/nrd733
Structure-based drug design: Cycle stopper
p96 | doi:10.1038/nrd734
Drug resistance: Hit where it hurts
p97 | doi:10.1038/nrd735
Cardiovascular disease: Why, why, why, Delilah?
p98 | doi:10.1038/nrd736
High-throughput screening: Molecular beacons for DNA binding
p98 | doi:10.1038/nrd737
G-Protein-coupled receptors: Putting the brake on inflammation
p99 | doi:10.1038/nrd738
In brief
Infectious disease | Pharmacogenetics | Neurodegenerative disease | Rational drug design
p99 | doi:10.1038/nrd740
In brief
Hyperlipidaemic disease | Neurodegenerative disease | Structure-based drug design
p100 | doi:10.1038/nrd739
Protein–protein interactions: Preventing tangles
p100 | doi:10.1038/nrd741
News and Analysis
From the analyst's couch
Market indicators
p101 | doi:10.1038/nrd742
Reviews
Efficacy at g-protein-coupled receptors
Terry Kenakin
p103 | doi:10.1038/nrd722
Apoptosis-based therapies
John C. Reed
p111 | doi:10.1038/nrd726
The potential for novel anti-inflammatory therapies for coronary artery disease
Margaret A. Cascieri
p122 | doi:10.1038/nrd723
Drug and gene targeting to the brain with molecular trojan horses
William M. Pardridge
p131 | doi:10.1038/nrd725
Novel drug development opportunities for heparin
Rebecca Lever & Clive P. Page
p140 | doi:10.1038/nrd724
Perspectives
Science and society
Animal experimentation: the continuing debate
Mark Matfield
p149 | doi:10.1038/nrd727
Innovation
Metabonomics: a platform for studying drug toxicity and gene function
Jeremy K. Nicholson, John Connelly, John C. Lindon & Elaine Holmes
p153 | doi:10.1038/nrd728
